SPECTRAL AI, INC. (MDAI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 9.71%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 9.71% | Share-based compensation / revenue. Period ending 2026-06-30. $1.49M ÷ $15.39M × 100 ≈ 9.71% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 15.39M USD | |
| Stock-based compensation | 1.49M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -11.88M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $15.39M | $1.49M | $-11.88M | (m) | (m) | 9.71% | (m) | (m) |
| 2026-03-31 | (m) | $16.93M | $1.10M | $-9.68M | (m) | (m) | 6.48% | (m) | (m) |
| 2025-12-31 | (m) | $19.65M | $1.11M | $-8.60M | (m) | (m) | 5.67% | (m) | (m) |
| 2025-09-30 | (m) | $23.17M | $1.05M | $-7.47M | (m) | (m) | 4.51% | (m) | (m) |
| 2025-06-30 | (m) | $27.55M | $958.00K | $-5.02M | (m) | (m) | 3.48% | (m) | (m) |
| 2025-03-31 | (m) | $29.96M | $949.00K | $-5.33M | (m) | (m) | 3.17% | (m) | (m) |
| 2024-12-31 | (m) | $29.58M | $1.03M | $-6.58M | (m) | (m) | 3.49% | (m) | (m) |
| 2024-09-30 | (m) | $27.26M | $1.13M | $-8.40M | (m) | (m) | 4.13% | (m) | (m) |
| 2024-06-30 | (m) | $22.53M | $1.23M | $-11.68M | (m) | (m) | 5.47% | (m) | (m) |
| 2024-03-31 | $15.40M | $19.30M | $1.23M | $-12.23M | (m) | 79.78% | 6.35% | (m) | (m) |
| 2023-12-31 | $15.10M | $18.06M | $1.24M | $-12.98M | (m) | 83.63% | 6.88% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | $-10.43M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $-2.54M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $-1.31M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $-1.25M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | $-2.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | $-3.69M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $-3.73M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $-3.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |